From the identification of actionable pharmacogenomic markers (such as IFNL3 and SLCO1B1) to the AI-driven proposal of baricitinib as a COVID-19 therapy, we now stand at the threshold of a more systematic, integrative, and evidence-responsive approach to therapeutic innovation. This evidence concerns the gene SLCO1B1 and COVID-19.